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a  b  s  t  r  a  c  t
Familial  hypercholesterolemia  (FH)  is  an  inherited  disorder  of blood  lipid  metabolism  characterized  by
high serum  low-density  lipoprotein  cholesterol  levels  and  premature  coronary  artery  disease.  In this
study,  we used  a system  biology  approach  to identify  co-expressed  gene  pairs  that were  potentiallyccepted 11 February 2013
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involved  in the  progression  of  FH  and  constructed  a conserved  co-expression  network  using  these  genes.
A total  of  4232  co-expressed  relationships  were  identiﬁed  and  we veriﬁed  the  signiﬁcance  by  random
permutation.  FH  patients  showed  differences  in lipoprotein  and  cholesterol  metabolism  in  circulating
monocytes  and lymphocytes  compared  to healthy  controls.  We  hope  our  study  could  aid in understanding
of  FH  and  could  provide  the  basis  for  FH  biomarker  identiﬁcation.
3  Japamilial hypercholesterolemia ©  201
ntroduction
Familial hypercholesterolemia (FH) is an inherited disorder of
lood lipid metabolism characterized by high serum low-density
ipoprotein (LDL) cholesterol levels. It is the most common and
ost severe of the single gene disorders of LDL metabolism.
he high level of serum LDL cholesterol frequently results in
xcess deposition of cholesterol in tissues, leading to accelerated
therosclerosis and increased risk of premature coronary artery
isease [1]. It is estimated that 85% of males and 50% of females
ith FH will suffer coronary artery disease before 65 years of age
2–4]. FH may  be loosely classiﬁed into “heterozygous” (one mutant
DL receptor allele) and “homozygous” (two mutated LDL recep-
or alleles) clinical phenotypes. Heterozygous FH occurs in 1:500
eople in the general population of most countries; homozygous
H is much rarer, occurring in 1 in a million births [5,6]. Although
tatins have been shown to reduce cholesterol levels in FH, they
ave not yet proven to be successful to cure this disease [7]. This
igh prevalence is sufﬁcient to warrant the diagnosis and treatment
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of FH at primary health care level according to the World Health
Organization.
Various attempts have been made to understand the patho-
genesis of FH in the past decades. FH is caused by mutations of
genes in sterol and lipoprotein pathways and displays varying gene-
dose effects [8]. To date, several genes have been identiﬁed as
diagnostic markers for FH. The most common genetic mutations
are LDL receptor (LDLR) mutations [9,10], apolipoprotein (apo) B
mutations [11], proprotein convertase subtilisin/kexin 9 (PCSK9)
mutations [12,13], and the autosomal recessive hypercholesterol-
emia (ARH) adaptor protein mutations [14]. Besides, the presence
of mutations in other candidate genes has been postulated in recent
years, such as CYP7A1 [15], SREP-2 [16], or SCAP [17]. But the evi-
dence that these mutations cause the phenotype is not strong. High
throughput molecular techniques have been widely used to bet-
ter understand the pathogenesis and progression of FH in recent
years. Most previous studies have focused on differential expres-
sion and have identiﬁed hundreds of differentially expressed genes
(DEGs) [18]. However, these investigations mostly focus on individ-
ual genes without consideration of potential relationships among
these genes.
It  has been shown that co-expressed genes are correlated with
functional relationships, such as physical interaction between the
encoded proteins [19,20]. From the perspective of system biology,
gene co-expression analysis is useful for investigating gene inter-
connection at the expression level. In this study, we implemented
a system biology approach and analyzed gene expression proﬁles
vier Ltd. All rights reserved.
Cardio
i
F
c
b
M
A
d
w
G
o
p
t
F
g
p
F
t
F
D
i
R
p
e
t
p
g
t
t
r
f
w
C
b
c
i
c
t
P
o
t
s
c
G
a
d
c
d
c
E
d
l
n
sY. Ye et al. / Journal of 
n 23 monocytes samples and 23 T cell samples from patients with
H compared with those from healthy controls. We  hope our study
ould aid in understanding of FH and could provide the basis for FH
iomarker identiﬁcation.
aterials and methods
ffymetrix microarray data
Two published microarray datasets (GSE6054 and GSE6088) of
ifferent leukocyte subsets from FH patients and healthy controls
ere used in our study. These datasets were downloaded from NCBI
EO database (http://www.ncbi.nlm.nih.gov/geo/) which is based
n Affymetrix Human Genome U133 Plus 2.0 Array. Both of the two
roﬁles were from Institute of Vascular Medicine, University Hospi-
al Juna. Gene expression proﬁles of homozygous and heterozygous
H from patients with documented genetic defects in the LDLR
ene were compared with healthy volunteers. The transcription
roﬁle of GSE6054 contains 23 monocyte samples: 4 homozygous
H, 6 heterozygous FH, and 13 control participants. The transcrip-
ion proﬁle of GSE6088 contains 23 T cell samples: 3 homozygous
H, 7 heterozygous FH, and 13 control participants.
ifferentially expressed genes analysis
For the GSE6054 and GSE6088 datasets, the t-test was used to
dentify DEGs, respectively. We  preprocessed the CEL source ﬁles by
MA  (Robust Multi-Array Average) algorithm [21] with defaulted
arameters in R [22] Affy package. Probe sets were mapped to NCBI
ntrez genes using DAVID [23]. If there were multiple probe sets
hat correspond to the same gene, the expression values of those
robe sets were averaged. If one probe corresponded to multiple
enes, the probe was deleted. All of the expression values were
hen converted to fold changes (FC) with log2 base. To circumvent
he multi-test problem which might induce too many false positive
esults, the BH method [24] was used to adjust the raw p-values into
alse discovery rate (FDR). The DEGs only with FDR less than 0.05
ere selected.
o-expression dysfunctional network construction
For demonstrating the potential regulatory relationship
etween DEGs, the Pearson correlation coefﬁcient (PCC) [25] was
alculated for all pair-wise comparisons of gene-expression values
n FH samples and healthy controls. In order to verify the signiﬁ-
ance of these co-expressed relationships, we randomly permuted
he gene expression proﬁles 100 times and then calculated the
CC of each gene pair after permutation. If the real PCC was  equal
r larger than the permuted PCC with a p-value less than 0.001,
hen we considered this relationship was signiﬁcant. And then, the
igniﬁcant co-expressed gene pairs were selected to construct a
o-expression dysfunctional network using Cytoscape [26].
ene ontology and pathway enrichment analysis
The gene ontology (GO) project is a collaborative effort to
ddress the need for consistent descriptions of gene products in
ifferent databases and utilizes a controlled GO vocabulary in a
urated database [27]. GO provides three structured networks of
eﬁned terms to describe gene product attributes: biological pro-
ess, molecular function, and cellular compartment. KEGG (Kyoto
ncyclopedia of Genes and Genomes) is a collection of online
atabases dealing with genomes, enzymatic pathways, and bio-
ogical chemicals [28]. The PATHWAY database in KEGG records
etworks of molecular interactions in the cells and variants of them
peciﬁc to particular organisms.logy 62 (2013) 58–62 59
To determine genes that represent biological processes and
pathways that were most affected in FH patients, the genes most
signiﬁcantly changed in expression level were mapped to the GO
and KEGG using the GOstats package [29] in R. The GOstats package
identiﬁed the over-represented GO categories in biological process
and KEGG pathway based on the hypergeometric distribution [30].
It was supposed that there were a total of N genes in all GO bio-
logical processes (or KEGG pathways), and n of them were DEGs,
m represented the number of DEGs in a given GO biological pro-
cess (or KEGG pathway), and then the p-value which k genes were
overlapping at least was calculated as follow:
p = 1 −
k−1∑
0
Cm
k
CN−m
n−k
CNn
The over-represented GO term with FDR less than 0.001 were
selected as the signiﬁcant category. The pathways that fulﬁlled the
criteria of FDR less than 0.01 were identiﬁed.
Results
Differentially expressed genes analysis
For the GSE6054 and GSE6088 datasets, the t-test was used to
identify the DEGs, respectively. The FDR less than 0.05 was chosen
as the cut-off criterion. Finally, a total of 1161 genes were identiﬁed
as DEGs of GSE6054 and a total of 6131 genes were identiﬁed as
DEGs of GSE6088. Of these, a total of 1024 overlapping genes were
used in the following analysis.
Dysfunctional co-expression network construction
By repeating the permutation procedure 100 times, 4232
co-expressed gene pairs between 871 DEGs were identiﬁed as
signiﬁcant dysfunctional pairs in FH (p < 0.001). Based on the
above relationships, a co-expression network was constructed by
Cytoscape (Fig. 1).
Functional annotation of the dysfunctional co-expression network
In order to investigate the co-expression network on a more
functional level, we used the GOstats and observed signiﬁcant
enrichment of these genes in multiple GO categories (Table 1).
Eighty-one GO biological processes were enriched with a FDR  less
than 0.001 and the top 20 signiﬁcant GO terms are shown in Table 1.
The most signiﬁcant enrichment was the GO category of primary
metabolic process with FDR = 4.62E−07. The other signiﬁcant GO
categories included cellular metabolic process (FDR = 6.20E−07)
and cellular metabolic process (FDR = 3.03E−06). In fact, all sig-
niﬁcant GO category clusters were related to metabolic process,
immune response, localization, and cell communication.
To gain further insights into the dysregulated pathways in
FH patients, we performed pathway enrichment analysis using
the KEGG pathways. Fourteen KEGG pathways were enriched
with a FDR less than 0.01 (Table 2), including chronic myeloid
leukemia (FDR = 0.0006808), neurotrophin signaling pathway
(FDR = 0.0011128), and SNARE interactions in vesicular transport
(FDR = 0.0014316).
DiscussionThe advent of DNA microarray technology, which facilitates
investigation to identify genes and biological pathways that are
associated with clinically deﬁned conditions [31], has provided
a powerful tool to understand the complex pathogenesis of
60 Y. Ye et al. / Journal of Cardiology 62 (2013) 58–62
Fig. 1. The dysfunctional co-ex
Table 1
Classiﬁcation of differentially co-expressed genes between healthy controls and
familial hypercholesterolemia patients according to gene ontology (GO) terms with
a  false discovery rate (FDR) < 0.001 (Top 20).
GO-ID Category FDR
GO:0044238 Primary metabolic process 4.62E−07
GO:0044260 Cellular macromolecule metabolic process 6.20E−07
GO:0044237 Cellular metabolic process 3.03E−06
GO:0006139 Nucleobase-containing compound metabolic
process
3.64E−06
GO:0043170 Macromolecule metabolic process 3.75E−06
GO:0002376 Immune system process 6.32E−06
GO:0016070 RNA metabolic process 1.39E−05
GO:0045087 Innate immune response 1.68E−05
GO:0050794 Regulation of cellular process 1.79E−05
GO:0090304 Nucleic acid metabolic process 2.40E−05
GO:0034641 Cellular nitrogen compound metabolic process 2.53E−05
GO:0006955 Immune response 2.74E−05
GO:0006950 Response to stress 2.75E−05
GO:0006807 Nitrogen compound metabolic process 3.88E−05
GO:0046907 Intracellular transport 4.11E−05
GO:0080134 Regulation of response to stress 4.42E−05
GO:0009987 Cellular process 4.46E−05
GO:0071310 Cellular response to organic substance 4.98E−05
GO:0008152 Metabolic process 5.14E−05
GO:0008104 Protein localization 6.57E−05pression network in FH.
heterogeneous diseases. However, most previous studies have
focused on differential expression and have produced large sets of
genes without consideration of potential relationships among these
genes. In this study, we constructed a conserved co-expression net-
work of DEGs in FH by combining DNA expression data sets from
human T cells and monocytes, and eventually characterized the
dysregulated biological processes and pathways.
Co-expressed genes are biologically related, grouping these
highly connected genes by network analysis may  shed light on
underlying functional processes in a manner complementary to
standard differential expression analyses [32]. Thus, identiﬁcation
of the co-expressed genes is important to analyze FH mechanisms.
In this study, we  identiﬁed a total of 4232 co-expression relation-
ships between 871 genes and veriﬁed the signiﬁcance by random
permutation. These co-expression relationships were dysregulated
in the progression of FH, and functional annotation of these rela-
tionships will shed light on the mechanisms underlying FH.
Functional annotation of the co-expression network enriched a
total of 81 biological processes and the top 20 signiﬁcant terms are
shown in Table 1. We  can ﬁnd that metabolic process accounts for a
high proportion of the enriched GO categories which suggests that
metabolism is disordered in the progression of FH. Our result was in
Y. Ye et al. / Journal of Cardio
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line with a previous study which suggested that FH is an autosomal
codominant inherited disorder of lipoprotein metabolism charac-
terized by high LDL cholesterol levels [33]. Many patients with FH
have mutations in the LDLR gene that encodes the LDL receptor pro-
tein, which normally removes LDL from the circulation, or ApoB,
which is the part of LDL that binds with the receptor or mutations
in other genes [34]. All of these mutations have in common resulted
in defective clearance of LDL within a complex system of lipid and
lipoprotein metabolism and regulation [8,35]. Our results suggest
that circulating monocytes and lymphocytes show differences in
lipoprotein and cholesterol metabolism.
Pathway analysis of the differentially co-expressed genes
showed that chronic myeloid leukemia, neurotrophin signaling
pathway, and SNARE interactions in vesicular transport belong to
the most prominently regulated signaling pathways in FH. So far,
no studies have reported these pathways to be dysregulated in
FH. However, we  observed that many members of MAPK family
were differentially expressed in FH, such as MAPK1, MAP3K1, and
MAPK9. Previous publications have shown that the MAPK pathways
are crucial for the development of atherosclerosis and are related
by oxdized LDL in a scavenger receptor-dependent manner [36].
The pathway of SNARE interactions in vesicular transport was
also enriched in our result with a p-value of 0.0014316. SNARE
(soluble N-ethylmaleimide-sensitive factor attachment protein
receptor) proteins are a family of membrane proteins that allow
fusion between membranes [37]. SNARE proteins play important
roles in mediating vesicle fusion through full fusion exocytosis or
kiss-and-run fusion exocytosis. That is, the exocytosis of cellular
transport vesicles with the cell membrane at the porosome or with
a target compartment [38,39]. In healthy individuals, cells ingest
cholesterol by endocytosis of LDL bound to the LDLR. After endo-
cytosis, the LDLR uncouples from its ligand and returns to the cell
surface, while the LDL is catabolized [40]. In our study, we  observed
many genes related to endocytosis were differentially expressed
in FH, such as members of syntaxin family (STX7, STX8, SNAP23),
golgi SNAP receptor complex (GOSR2), and vesicle-associated pro-
tein (VTI1A, VAMP8). From our results, we  hypothesized that the
transport of LDLR via the pathway of SNARE interactions in vesic-
ular transport is dysfunctional in FH. However, as the number of
subjects was  limited in our study, the evidence remains incon-
clusive. Further experimental analysis is needed to conﬁrm our
hypothesis.
Conclusion
This study used a system biology approach to identify co-
expressed genes that are potentially involved in the development
of FH and constructed a conserved co-expression network of DEGs.
This approach moves beyond single gene investigation to provide
a system level perspective on the potential relationships between
members of a network. Our results suggest that FH patients showed
differences in lipoprotein and cholesterol metabolism in circulating
monocytes and lymphocytes compared to healthy controls. A fur-
ther investigation of our co-expression network may contribute to
understanding the complex interacting mechanisms of transcrip-
tion factors and their regulated genes in FH.
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